ONCT

Oncternal Therapeutics (ONCT)

About Oncternal Therapeutics (ONCT)

Oncternal Therapeutics, Inc. engages in the development of novel oncology therapies for the treatment of cancers with critical unmet medical need. Its product pipeline include Zilovertamab, ONCT-216, ONCT-808 and ONCT-534. The company was founded by David F. Hale and James B. Breitmeyer in September 1997 and is headquartered in San Diego, CA.

Details

Daily high

$1.25

Daily low

$1.22

Price at open

$1.23

52 Week High

$13.14

52 Week Low

$1.20

Market cap

3.7M

Dividend yield

0.00%

Volume

15,562

Avg. volume

106,617

P/E ratio

-.10

Oncternal Therapeutics News